Showing results (51-60 of 92) with videos related to
Sort By:
Pageof 10
International Journal of Radiation Oncology, Biology, Physics|September 21, 2007
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinomaBrian G Czito, Darrel P Cohen, Chris R Kelsey, et al.Investigational New Drugs|March 19, 2021
Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I studyKatrina S Pedersen, Patrick M Grierson, Joel Picus, et al.Journal of Gastrointestinal Oncology|March 17, 2020
Phase Ib/II study combining tosedostat with capecitabine in patients with advanced pancreatic adenocarcinomaPatrick Grierson, Andrea Teague, Rama Suresh, et al.Cancer Medicine|November 16, 2017
Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer DatabaseGregory Vlacich, Pamela P Samson, Stephanie M Perkins, et al.Targeted Oncology|May 13, 2014
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumabJosep Tabernero, Sant P Chawla, Hedy Kindler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 3, 2014
Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancerVenkataswarup Tiriveedhi, Natalia Tucker, John Herndon, et al.Clinical and Translational Radiation Oncology|July 19, 2021
A single-institution phase I feasibility study of dose-escalated IMRT for non-operative locally advanced esophageal carcinomaGregory Vlacich, Andrew Ballard, Shahed N Badiyan, et al.Cancer Chemotherapy and Pharmacology|November 7, 2020
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumorsHaeseong Park, Kerry Williams, Nikolaos A Trikalinos, et al.Journal of Gastrointestinal Oncology|January 5, 2018
Pacritinib to inhibit JAK/STAT signaling in refractory metastatic colon and rectal cancerThomas Regenbogen, Ling Chen, Kathryn Trinkaus, et al.Investigational New Drugs|December 2, 2015
A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumorsManik Amin, Susan E Minton, Patricia M LoRusso, et al.Pageof 10